Methods for the treatment of HER2-positive breast cancer are provided by neoadjuvant administration of pertuzumab and trastuzumab in combination with anthracycline-based chemotherapy. In particular, the methods concerns the treatment patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer by neoadjuvant administration of pertuzumab and trastuzumab following anthracycline-based chemotherapy, wherein the combined administration of pertuzumab and trastuzumab increases pathological complete response (pCR) relative to administration of trastuzumab as a single agent, without significant increase in adverse events, such as cardiac toxicity, relative to neoadjuvant anthracycline-based chemotherapy.提供用於治療HER2陽性乳癌之方法，其係藉由與基於蒽環黴素的化療組合新輔助性投與帕妥珠單抗及曲妥珠單抗來進行。特別地，該方法涉及藉由在基於蒽環黴素的化療之後以新輔助性方式投與帕妥珠單抗及曲妥珠單抗來治療患有HER2陽性、局部晚期、炎性或早期乳癌之患者，其中相對於以單一藥劑形式投與曲妥珠單抗，帕妥珠單抗及曲妥珠單抗之組合投與增加病理學完全反應(pCR)而相對於新輔助性基於蒽環黴素的化療，不利事件諸如心臟毒性未顯著增加。
